Pacira BioSciences, Inc. (PCRX)
Makes pain-relief drugs and devices that work without opioids
$26.81+0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+21.5%
The outlook
PCRX is trading near the upper end of its 52-week range and above both its 50- and 200-day moving averages, signaling upward momentum. Analysts lean bullish overall, with an average price target about 11% above the current price. The stock carries a notably high trailing P/E ratio of 206, reflecting elevated valuation relative to current earnings.
What’s behind the score
Analyst consensusBuy — 2.3 avg of 6 analysts
Price trendAbove its 50- & 200-day averages
52-week range91% of the way from its 52-week low to high
Price targetAvg target +11% vs current price
Analyst price target
~12-month · 6 analysts$29.67average target+10.7% vs now
Now $26.81
Low $23.00High $38.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.05B
52-wk high
$27.64
52-wk low
$18.80
50-day avg
$24.12
200-day avg
$23.41
Trailing P/E
206.2